Angiodynamics (ANGO) Net Income towards Common Stockholders (2010 - 2026)

Angiodynamics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 83.44% year-over-year to -$8.1 million; the trailing twelve-month figure through Feb 2026 stood at -$31.4 million (up 24.17% YoY), and the FY2025 full-year result was -$34.0 million, up 81.56% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$8.1 million, down from -$6.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $45.9 million in Q3 2023, with the low at -$187.7 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$18.1 million across 5 years, with a median of -$9.5 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 452.85% — and 2024, when it slumped 1879.29%.
• Angiodynamics' Net Income towards Common Stockholders stood at -$8.5 million in 2022, then slumped by 242.3% to -$29.0 million in 2023, then jumped by 63.03% to -$10.7 million in 2024, then soared by 40.86% to -$6.4 million in 2025, then slipped by 27.31% to -$8.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$8.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.